Edgewise Therapeutics
EWTX
85 hedge funds and large institutions have $443M invested in Edgewise Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 14 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
0.08% less ownership
Funds ownership: 105.13% → 105.05% (-0.08%)
6% less funds holding
Funds holding: 90 → 85 (-5)
25% less capital invested
Capital invested by funds: $594M → $443M (-$151M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
83% less call options, than puts
Call options by funds: $11K | Put options by funds: $64K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.8M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$6.33M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$4.63M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.28M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$6.03M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.01M |
| 3 |
Goldman Sachs
New York
|
-$2.88M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.84M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$1.68M |
EWTX Hedge Fund Activity: Q1 2023 in Review
85 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2023, worth a combined $443M — down 25% from $594M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of EWTX and 9 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 30 added.
The largest buyer was Granahan Investment Management, opening a new position worth an estimated $6.8M. The largest seller was Janus Henderson Group, cutting an estimated $6.03M.
- 85 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2023, down from 90 in Q4 2022.
- Funds reported $443M of Edgewise Therapeutics stock for Q1 2023, down 25% quarter-over-quarter.
- 9 funds opened new Edgewise Therapeutics positions in Q1 2023 and 14 closed out, a net change of -5 holders.
- The largest Edgewise Therapeutics buyer in Q1 2023 was Granahan Investment Management, an estimated $6.8M added.
- The largest Edgewise Therapeutics seller in Q1 2023 was Janus Henderson Group, an estimated $6.03M sold.
Based on aggregated 13F filings for Q1 2023.